NetworkNewsBreaks – IntelGenx Corp. (IGXT) Shares Nudge Higher on License for Tadalafil Erectile Dysfunction Dosing Patent
IntelGenx Corp. (OTCQX: IGXT) is trading higher on word the company, with Eli Lilly (NYSE: LLY), has secured a license for the tadalafil erectile dysfunction dosing patent. Upon FDA approval, the license will allow IntelGenx to commercialize its Tadalafil ED VersaFilm™ product in the U.S. before the expiration of the patent. IntelGenx said it intends to file an NDA with the FDA in the second quarter of 2017 followed by a U.S. launch of the ED product, upon approval, the following year. To view the full press release, visit: http://nnw.fm/Uk2U4 About IntelGenx IntelGenx is a leading oral drug delivery company…